Accessibility Menu
Arrow-Thin-Down
S&P 500
6,939.03
-0.4%
-29.98
Arrow-Thin-Down
DJI
48,892.47
-0.4%
-179.09
Arrow-Thin-Down
NASDAQ
23,461.82
-0.9%
-223.30
Arrow-Thin-Down
Bitcoin
$77,107.00
-0.4%
-$341.93
Arrow-Thin-Down
TCGL
$172.84
+100.1%
+$86.48
Arrow-Thin-Down
SNDK
$574.89
+6.6%
+$35.59
Arrow-Thin-Down
VZ
$44.52
+11.8%
+$4.71
Arrow-Thin-Down
DECK
$119.34
+19.5%
+$19.44
Arrow-Thin-Down
RKT
$17.93
-13.7%
-$2.84
Arrow-Thin-Down
U
$29.03
-24.4%
-$9.37
Arrow-Thin-Down
AMZN
$239.26
-1.0%
-$2.47
Arrow-Thin-Down
GOOG
$338.58
-0.0%
-$0.08
Arrow-Thin-Down
META
$716.50
-3.0%
-$21.81
Arrow-Thin-Down
MSFT
$429.91
-0.8%
-$3.59
Arrow-Thin-Down
NVDA
$191.13
-0.7%
-$1.38
Arrow-Thin-Down
TSLA
$430.62
+3.4%
+$14.06
Daily Stock GainersDaily Stock LosersMost Active Stocks

Why Hims & Hers Stock Is Crashing, and Is It a Buying Opportunity?

By Parkev Tatevosian, CFA – Jun 26, 2025 at 7:00AM EST

Novo Nordisk (NVO +0.17%) severed its partnership with Hims & Hers (HIMS 9.31%), arguing that the company breached the agreement between the two.

*Stock prices used were the afternoon prices of June 22, 2025. The video was published on June 24, 2025.

Read Next

About the Author

Parkev Tatevosian, CFA
A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history. You'll often find him writing about stocks in the consumer goods and technology sectors.
TMFParkev
X@TMFParkev

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Stocks Mentioned

Hims & Hers Health Stock Quote

Hims & Hers Health

NYSE: HIMS
$27.09 (0.09%) $2.78
Novo Nordisk Stock Quote

Novo Nordisk

NYSE: NVO
$59.43 (+0.00%) $+0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services